FDA Approves Oxervate (cenegermin) for Neurotrophic Keratitis

August 22, 2018 -- The U.S. Food and Drug Administration today approved the first drug, Oxervate (cenegermin), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea (the clear layer that covers the colored portion of the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news